Ionis Pharmaceuticals, Inc. (0JDI.L)
USD 37.31
(-0.8%)
USD 37.31
(-0.8%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 779.58 Million USD | 15.06% |
| 2022 | 984 Million USD | 18.7% |
| 2021 | 829 Million USD | -6.75% |
| 2020 | 889 Million USD | 18.06% |
| 2019 | 753 Million USD | 14.22% |
| 2018 | 659.22 Million USD | 36.45% |
| 2017 | 483.13 Million USD | 22.95% |
| 2016 | 392.93 Million USD | 9.31% |
| 2015 | 359.46 Million USD | 37.26% |
| 2014 | 261.89 Million USD | 31.64% |
| 2013 | 198.95 Million USD | 16.36% |
| 2012 | 170.97 Million USD | 0.46% |
| 2011 | 170.18 Million USD | 8.52% |
| 2010 | 156.82 Million USD | 5.16% |
| 2009 | 149.13 Million USD | 24.02% |
| 2008 | 120.25 Million USD | 10.76% |
| 2007 | 108.56 Million USD | 16.51% |
| 2006 | 93.18 Million USD | 3.13% |
| 2005 | 90.35 Million USD | -29.44% |
| 2004 | 128.05 Million USD | 0.7% |
| 2003 | 127.16 Million USD | -1.89% |
| 2002 | 129.61 Million USD | 30.43% |
| 2001 | 99.37 Million USD | 38.44% |
| 2000 | 71.78 Million USD | -12.68% |
| 1999 | 82.2 Million USD | 8.16% |
| 1998 | 76 Million USD | 13.1% |
| 1997 | 67.2 Million USD | 23.3% |
| 1996 | 54.5 Million USD | 31.64% |
| 1995 | 41.4 Million USD | 13.74% |
| 1994 | 36.4 Million USD | 355.0% |
| 1993 | 8 Million USD | -75.23% |
| 1992 | 32.3 Million USD | 509.43% |
| 1991 | 5.3 Million USD | 152.38% |
| 1990 | 2.1 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 261.2 Million USD | -20.26% |
| 2024 Q2 | 281.59 Million USD | 7.81% |
| 2023 Q3 | 285 Million USD | 3.26% |
| 2023 Q4 | 327.55 Million USD | 14.93% |
| 2023 FY | 1.13 Billion USD | 15.06% |
| 2023 Q1 | 244 Million USD | -31.46% |
| 2023 Q2 | 276 Million USD | 13.11% |
| 2022 Q1 | 195.22 Million USD | -10.03% |
| 2022 Q2 | 214.55 Million USD | 9.9% |
| 2022 Q3 | 217.39 Million USD | 1.32% |
| 2022 Q4 | 356 Million USD | 63.76% |
| 2022 FY | 984 Million USD | 18.7% |
| 2021 FY | 829 Million USD | -6.75% |
| 2021 Q1 | 196.9 Million USD | -36.48% |
| 2021 Q2 | 184.4 Million USD | -6.35% |
| 2021 Q4 | 217 Million USD | 0.99% |
| 2021 Q3 | 214.87 Million USD | 16.52% |
| 2020 Q1 | 191.94 Million USD | -17.26% |
| 2020 FY | 889 Million USD | 18.06% |
| 2020 Q2 | 194.27 Million USD | 1.22% |
| 2020 Q3 | 193.53 Million USD | -0.39% |
| 2020 Q4 | 310 Million USD | 60.18% |
| 2019 FY | 753 Million USD | 14.22% |
| 2019 Q1 | 174.63 Million USD | -3.28% |
| 2019 Q3 | 164.4 Million USD | -9.67% |
| 2019 Q2 | 182 Million USD | 4.22% |
| 2019 Q4 | 232 Million USD | 41.12% |
| 2018 Q2 | 168.02 Million USD | 13.75% |
| 2018 Q4 | 180.55 Million USD | 10.12% |
| 2018 FY | 659.22 Million USD | 36.45% |
| 2018 Q3 | 163.96 Million USD | -2.42% |
| 2018 Q1 | 147.72 Million USD | -15.1% |
| 2017 FY | 483.13 Million USD | 22.95% |
| 2017 Q1 | 96.31 Million USD | -19.19% |
| 2017 Q4 | 173.99 Million USD | 62.61% |
| 2017 Q3 | 107 Million USD | 1.11% |
| 2017 Q2 | 105.82 Million USD | 9.87% |
| 2016 Q4 | 119.19 Million USD | 25.71% |
| 2016 Q2 | 87.39 Million USD | -4.51% |
| 2016 Q3 | 94.81 Million USD | 8.49% |
| 2016 FY | 392.93 Million USD | 9.31% |
| 2016 Q1 | 91.52 Million USD | -20.07% |
| 2015 Q4 | 114.51 Million USD | 17.74% |
| 2015 Q1 | 71.91 Million USD | -3.84% |
| 2015 Q2 | 75.78 Million USD | 5.38% |
| 2015 Q3 | 97.25 Million USD | 28.34% |
| 2015 FY | 359.46 Million USD | 37.26% |
| 2014 Q2 | 63.72 Million USD | 10.2% |
| 2014 FY | 261.89 Million USD | 31.64% |
| 2014 Q4 | 74.78 Million USD | 14.07% |
| 2014 Q1 | 57.82 Million USD | -6.89% |
| 2014 Q3 | 65.55 Million USD | 2.87% |
| 2013 Q3 | 49.09 Million USD | 6.67% |
| 2013 FY | 198.95 Million USD | 16.36% |
| 2013 Q4 | 62.1 Million USD | 26.51% |
| 2013 Q2 | 46.02 Million USD | 10.27% |
| 2013 Q1 | 41.73 Million USD | -9.26% |
| 2012 Q3 | 39.64 Million USD | -9.16% |
| 2012 Q1 | 41.69 Million USD | -18.29% |
| 2012 Q4 | 45.99 Million USD | 16.0% |
| 2012 FY | 170.97 Million USD | 0.46% |
| 2012 Q2 | 43.64 Million USD | 4.69% |
| 2011 Q4 | 51.01 Million USD | 18.57% |
| 2011 FY | 170.18 Million USD | 8.52% |
| 2011 Q1 | 37.25 Million USD | -11.88% |
| 2011 Q2 | 38.88 Million USD | 4.37% |
| 2011 Q3 | 43.02 Million USD | 10.66% |
| 2010 FY | 156.82 Million USD | 5.16% |
| 2010 Q4 | 42.27 Million USD | 12.53% |
| 2010 Q2 | 42.17 Million USD | 21.17% |
| 2010 Q1 | 34.8 Million USD | -20.77% |
| 2010 Q3 | 37.57 Million USD | -10.92% |
| 2009 FY | 149.13 Million USD | 24.02% |
| 2009 Q3 | 37.16 Million USD | 3.76% |
| 2009 Q2 | 35.81 Million USD | 11.18% |
| 2009 Q4 | 43.93 Million USD | 18.2% |
| 2009 Q1 | 32.21 Million USD | 84.81% |
| 2008 Q2 | 36.09 Million USD | 19.58% |
| 2008 Q4 | 17.43 Million USD | -52.29% |
| 2008 FY | 120.25 Million USD | 10.76% |
| 2008 Q1 | 30.18 Million USD | -9.0% |
| 2008 Q3 | 36.53 Million USD | 1.23% |
| 2007 Q3 | 28.57 Million USD | 21.73% |
| 2007 FY | 108.56 Million USD | 16.51% |
| 2007 Q1 | 23.35 Million USD | -18.81% |
| 2007 Q2 | 23.47 Million USD | 0.52% |
| 2007 Q4 | 33.17 Million USD | 16.09% |
| 2006 FY | 93.18 Million USD | 3.13% |
| 2006 Q4 | 28.76 Million USD | 31.95% |
| 2006 Q3 | 21.79 Million USD | 0.48% |
| 2006 Q2 | 21.69 Million USD | 3.6% |
| 2006 Q1 | 20.93 Million USD | -11.56% |
| 2005 Q3 | 19.95 Million USD | -12.74% |
| 2005 Q4 | 23.67 Million USD | 18.66% |
| 2005 Q2 | 22.86 Million USD | -4.19% |
| 2005 FY | 90.35 Million USD | -29.44% |
| 2005 Q1 | 23.86 Million USD | -22.41% |
| 2004 FY | 128.05 Million USD | 0.7% |
| 2004 Q1 | 34.63 Million USD | 11.09% |
| 2004 Q2 | 31.18 Million USD | -9.97% |
| 2004 Q3 | 31.47 Million USD | 0.93% |
| 2004 Q4 | 30.75 Million USD | -2.28% |
| 2003 Q4 | 31.17 Million USD | 2.69% |
| 2003 Q2 | 32.73 Million USD | -0.48% |
| 2003 FY | 127.16 Million USD | -1.89% |
| 2003 Q1 | 32.89 Million USD | 3.66% |
| 2003 Q3 | 30.36 Million USD | -7.25% |
| 2002 Q1 | 27.67 Million USD | -5.99% |
| 2002 Q4 | 31.73 Million USD | -16.07% |
| 2002 Q3 | 37.8 Million USD | 16.69% |
| 2002 Q2 | 32.4 Million USD | 17.06% |
| 2002 FY | 129.61 Million USD | 30.43% |
| 2001 FY | 99.37 Million USD | 38.44% |
| 2001 Q1 | 21.86 Million USD | -6.88% |
| 2001 Q4 | 29.44 Million USD | 22.61% |
| 2001 Q3 | 24.01 Million USD | -0.19% |
| 2001 Q2 | 24.05 Million USD | 10.01% |
| 2000 Q4 | 23.48 Million USD | 29.93% |
| 2000 Q1 | 15.06 Million USD | -44.62% |
| 2000 Q3 | 18.07 Million USD | 19.22% |
| 2000 Q2 | 15.16 Million USD | 0.64% |
| 2000 FY | 71.78 Million USD | -12.68% |
| 1999 Q3 | 18.7 Million USD | -2.6% |
| 1999 FY | 82.2 Million USD | 8.16% |
| 1999 Q4 | 27.2 Million USD | 45.45% |
| 1999 Q1 | 17.1 Million USD | -21.2% |
| 1999 Q2 | 19.2 Million USD | 12.28% |
| 1998 Q3 | 18.8 Million USD | 0.0% |
| 1998 Q4 | 21.7 Million USD | 15.43% |
| 1998 Q2 | 18.8 Million USD | 11.9% |
| 1998 Q1 | 16.8 Million USD | -27.27% |
| 1998 FY | 76 Million USD | 13.1% |
| 1997 FY | 67.2 Million USD | 23.3% |
| 1997 Q2 | 15.5 Million USD | 14.81% |
| 1997 Q3 | 15.2 Million USD | -1.94% |
| 1997 Q1 | 13.5 Million USD | -27.81% |
| 1997 Q4 | 23.1 Million USD | 51.97% |
| 1996 Q4 | 18.7 Million USD | 58.47% |
| 1996 Q1 | 11.2 Million USD | -9.68% |
| 1996 FY | 54.5 Million USD | 31.64% |
| 1996 Q3 | 11.8 Million USD | -7.81% |
| 1996 Q2 | 12.8 Million USD | 14.29% |
| 1995 Q3 | 11.1 Million USD | 19.35% |
| 1995 Q4 | 12.4 Million USD | 11.71% |
| 1995 FY | 41.4 Million USD | 13.74% |
| 1995 Q2 | 9.3 Million USD | 6.9% |
| 1995 Q1 | 8.7 Million USD | -33.08% |
| 1994 Q2 | 7.9 Million USD | 11.27% |
| 1994 Q3 | 8.2 Million USD | 3.8% |
| 1994 Q4 | 13 Million USD | 58.54% |
| 1994 FY | 36.4 Million USD | 355.0% |
| 1994 Q1 | 7.1 Million USD | 147.02% |
| 1993 Q2 | 7.8 Million USD | 0.0% |
| 1993 Q4 | -15.1 Million USD | -296.1% |
| 1993 FY | 8 Million USD | -75.23% |
| 1993 Q1 | 7.8 Million USD | -70.23% |
| 1993 Q3 | 7.7 Million USD | -1.28% |
| 1992 FY | 32.3 Million USD | 509.43% |
| 1992 Q2 | 1.9 Million USD | -5.0% |
| 1992 Q1 | 2 Million USD | 17.65% |
| 1992 Q3 | 1.9 Million USD | 0.0% |
| 1992 Q4 | 26.2 Million USD | 1278.95% |
| 1991 Q2 | 4 Million USD | 344.44% |
| 1991 Q3 | 1.2 Million USD | -70.0% |
| 1991 Q4 | 1.7 Million USD | 41.67% |
| 1991 FY | 5.3 Million USD | 152.38% |
| 1991 Q1 | 900 Thousand USD | 113.85% |
| 1990 Q3 | - USD | 0.0% |
| 1990 Q4 | -6.5 Million USD | 0.0% |
| 1990 Q1 | - USD | 0.0% |
| 1990 FY | 2.1 Million USD | 0.0% |
| 1990 Q2 | - USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Editas Medicine, Inc. | 247.3 Million USD | -215.234% |
| Dynavax Technologies Corporation | 219.14 Million USD | -255.74% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | -47.367% |
| Perrigo Company plc | 1.52 Billion USD | 48.997% |
| Illumina, Inc. | 3.81 Billion USD | 79.554% |
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 92.397% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | -72.86% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 98.08% |
| IQVIA Holdings Inc. | 2.05 Billion USD | 62.027% |
| Heron Therapeutics, Inc. | 120.65 Million USD | -546.118% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 72.309% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -1645.331% |
| Waters Corporation | 943.51 Million USD | 17.374% |
| Biogen Inc. | 5.2 Billion USD | 85.022% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -240.907% |
| Evolus, Inc. | 189.75 Million USD | -310.83% |
| Adicet Bio, Inc. | 152.03 Million USD | -412.758% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -447.221% |
| bluebird bio, Inc. | 240.23 Million USD | -224.514% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | -186.721% |
| FibroGen, Inc. | 398.11 Million USD | -95.821% |
| Agilent Technologies, Inc. | 2.11 Billion USD | 63.14% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -5504.652% |
| Homology Medicines, Inc. | 9.87 Million USD | -7794.552% |
| Geron Corporation | 70.44 Million USD | -1006.723% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 56.691% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | -82.295% |
| Myriad Genetics, Inc. | 600.1 Million USD | -29.91% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -673.193% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | -41.341% |
| Zoetis Inc. | 2.76 Billion USD | 71.805% |
| Abeona Therapeutics Inc. | 48.5 Million USD | -1507.33% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 28.438% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 55.357% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 83.674% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -1891.13% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -182.774% |
| Verastem, Inc. | 92.08 Million USD | -746.604% |
| Nektar Therapeutics | 190.9 Million USD | -308.368% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | -63.655% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -6321.11% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 42.712% |
| OPKO Health, Inc. | 574.68 Million USD | -35.654% |
| Exelixis, Inc. | 1.58 Billion USD | 50.87% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 51.169% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | -111.493% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -1298.212% |
| uniQure N.V. | 285.08 Million USD | -173.457% |
| Imunon, Inc. | 21.03 Million USD | -3606.948% |
| Blueprint Medicines Corporation | 722.86 Million USD | -7.847% |
| Insmed Incorporated | 949.26 Million USD | 17.874% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | -160.454% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | -90.699% |
| TG Therapeutics, Inc. | 198.47 Million USD | -292.789% |
| Incyte Corporation | 1.19 Billion USD | 34.516% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 25.327% |